Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 19.52%4.62B | 15.17%1.31B | 16.58%1.02B | 44.05%1.23B | 6.05%1.06B | -5.58%3.87B | 17.52%1.13B | -5.09%874.77M | -36.36%855.76M | 15.99%1B |
Cost of revenue | 38.70%1.95B | 32.52%565.09M | 34.55%421.42M | 77.19%546.64M | 16.62%419.3M | 5.39%1.41B | 44.25%426.42M | 5.35%313.19M | -33.39%308.51M | 28.62%359.54M |
Gross profit | 8.54%2.67B | 4.71%741.28M | 6.56%598.4M | 25.37%686.06M | 0.14%643.5M | -10.89%2.46B | 5.73%707.91M | -10.07%561.57M | -37.92%547.25M | 9.96%642.59M |
Operating expense | 12.86%2.08B | 5.43%538.68M | 5.18%481M | 19.99%515.95M | 22.46%541.71M | -15.06%1.84B | -2.55%510.93M | -9.60%457.29M | -37.71%430M | -0.93%442.37M |
Operating profit | -4.34%591.9M | 2.85%202.59M | 12.58%117.4M | 45.09%170.11M | -49.16%101.79M | 4.35%618.73M | 35.58%196.98M | -12.06%104.28M | -38.68%117.25M | 45.24%200.23M |
Net non-operating interest income (expenses) | -67.63%493K | -41.46%627K | -310.38%-223K | 29.38%207K | -163.44%-118K | 41.67%1.52M | 1,812.50%1.07M | 3,433.33%106K | -84.69%160K | 741.38%186K |
Non-operating interest income | -4.99%1.49M | -3.01%1.03M | -84.31%24K | 159.09%399K | -84.38%30K | 45.40%1.56M | 221.18%1.06M | -80.31%153K | -86.83%154K | 2,642.86%192K |
Non-operating interest expense | 2,380.00%992K | 5,885.71%405K | 425.53%247K | 3,300.00%192K | 2,366.67%148K | --40K | 99.25%-7K | -93.93%47K | -104.84%-6K | -83.33%6K |
Net investment income | 318.81%2.13M | 194.67%3.7M | 19.18%-2.64M | 156.33%965K | -96.36%100K | -125.24%-973K | -52.08%1.26M | -1,731.50%-3.26M | -258.17%-1.71M | 5,706.12%2.75M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -4,703.03%-100M | -5,496.65%-100.24M | 74.39%-2.34M | -30.42%2.58M | 0 | -118.90%-2.08M | -403.56%-1.79M | -887.18%-9.15M | -59.53%3.71M | 4,997.03%5.15M |
Income from associates and other participating interests | 1,646.53%60.16M | 133.17%2.9M | 74.93%-4.87M | 52.36%-2.73M | 116.28%64.86M | -110.57%-3.89M | -90.66%-8.74M | -413.19%-19.42M | -178.62%-5.72M | -20.86%29.99M |
Special income (charges) | -316.98%-28.58M | -136,921.43%-19.16M | -522.72%-10.09M | 116.95%13.17M | -95.33%14K | -31.91%2.39M | ||||
Less:Other special charges | 442.76%29.5M | --19.42M | --10.09M | ---- | ---- | -279.50%-8.61M | --0 | --0 | ---- | ---- |
Less:Write off | 79.89%-918K | -1,778.57%-263K | --0 | ---- | ---- | -20.03%-4.57M | 95.33%-14K | ---2.39M | ---- | ---- |
Other non-operating income (expenses) | 125.19%7.02M | 171.87%5.33M | -53.76%-5.66M | -106.92%-256K | 569.96%7.6M | 272.63%3.12M | 569.78%1.96M | -919.38%-3.68M | 364.92%3.7M | 357.95%1.14M |
Income before tax | -15.32%533.12M | -49.80%95.76M | 28.52%91.58M | 33.85%171.54M | -27.23%174.23M | -3.13%629.6M | 32.60%190.75M | -40.67%71.26M | -39.16%128.16M | 36.55%239.43M |
Income tax | -10.50%184.66M | -9.03%59.42M | -14.71%36.25M | 20.32%47.63M | -29.80%41.36M | 16.41%206.33M | 48.13%65.32M | 44.02%42.51M | -51.68%39.58M | 171.30%58.92M |
Net income | -17.67%348.46M | -71.03%36.34M | 92.41%55.33M | 39.90%123.92M | -26.39%132.87M | -10.46%423.27M | 25.73%125.43M | -68.26%28.76M | -31.19%88.58M | 17.50%180.51M |
Net income continuous operations | -17.67%348.46M | -71.03%36.34M | 92.42%55.33M | 39.90%123.92M | -26.39%132.87M | -10.46%423.27M | 25.73%125.43M | -68.26%28.76M | -31.19%88.58M | 17.50%180.51M |
Noncontrolling interests | -719K | 297K | -2M | 1.65M | -671K | 0 | 0 | 0 | 0 | 0 |
Net income attributable to the company | -17.50%349.18M | -71.27%36.04M | 99.37%57.33M | 38.03%122.26M | -26.02%133.55M | -10.46%423.27M | 25.73%125.43M | -68.26%28.76M | -31.19%88.58M | 17.50%180.51M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -17.50%349.18M | -71.27%36.04M | 99.37%57.33M | 38.03%122.26M | -26.02%133.55M | -10.46%423.27M | 25.73%125.43M | -68.26%28.76M | -31.19%88.58M | 17.50%180.51M |
Gross dividend payment | ||||||||||
Basic earnings per share | -17.07%46.89 | -70.87%4.88 | 102.62%7.74 | 38.88%16.43 | -26.10%17.84 | -8.67%56.54 | 26.70%16.75 | -68.22%3.82 | -30.00%11.83 | 22.10%24.14 |
Diluted earnings per share | -17.02%46.76 | -70.84%4.87 | 102.36%7.73 | 39.05%16.38 | -26.07%17.78 | -8.57%56.35 | 26.90%16.7 | -68.09%3.82 | -29.67%11.78 | 21.77%24.05 |
Dividend per share | 40.00%7 | 40.00%7 | 0 | 0 | 0 | 66.67%5 | 66.67%5 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |